Pro­to­cols: In­fin­i­ty hunts up a buy­er for its dis­ap­point­ing can­cer drug du­velis­ib; Is North­west Bio fi­nal­ly broke?

Ab­b­Vie’s de­ci­sion to abrupt­ly pull out of its part­ner­ship with In­fin­i­ty on du­velis­ib large­ly wrecked the com­pa­ny’s hopes to fi­nal­ly make it big af­ter re­peat­ed set­backs over the years. But In­fin­i­ty CEO Ade­lene Perkins isn’t giv­ing up. She tells BioWorld that the com­pa­ny is push­ing ahead in search of an ac­cel­er­at­ed ap­proval – the drug hit its end­point but looked com­mer­cial­ly fee­ble – while scout­ing for an­oth­er com­pa­ny will­ing to buy it. “We have sev­er­al par­ties who are in­ter­est­ed [in du­velis­ib] and we’re in dis­cus­sions,” Perkins told the news group.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.